Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA
Mylan Pharmaceuticals Inc. is accusing the U.S. Food and Drug Administration of stalling on a decision that could give Ranbaxy Laboratories Ltd. exclusive rights to market a generic version of the...To view the full article, register now.
Already a subscriber? Click here to view full article